VIDEO: Duker shares EyePoint pipeline progress

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.
“The DAVIO 2 trial consisted of 160 patients randomly assigned to either 2 mg of EYP-1901 or 3 mg of EYP-1901 vs. an on-label aflibercept control,” Duker said. “The topline results showed that both doses of EYP-1901 were both essentially were equivalent for visual acuity to the on-label aflibercept; however, EYP-1901 can last between 6 months and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart